Home Newsfeeds Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Keybanc analyst Michael Turits maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $63 to $60.

byBenzinga Newsdesk

December 6, 2022

1 minute read

Keybanc analyst Michael Turits maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $63 to $60.

Insiders Buying Dorian LPG And 2 Other Stocks

By Avi Kapoor

January 17, 7:23 AM

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

AVDL

FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects

By Nina Zdinjak

November 3, 9:24 AM

Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50

JAZZ

Abercrombie & Fitch’s Q2 Highlights: Earnings Miss, Inflation Hit Hollister Performance, Dismal Outlook & More

By Shivani Kumaresan

August 25, 12:50 PM

Abercrombie & Fitch Co (NYSE:ANF) reported a second-quarter FY22 sales decline of 7% year-on-year to $805.09 million, missing the consensus of…

ANF

Analyst Ratings

7 Analysts Have This to Say About Health Catalyst

By Benzinga Insights

October 25, 4:46 PM

Over the past 3 months, 7 analysts have published their opinion on Health Catalyst (NASDAQ:HCAT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

HCAT

Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Related Posts

Insiders Buying Dorian LPG And 2 Other Stocks

FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects

Abercrombie & Fitch’s Q2 Highlights: Earnings Miss, Inflation Hit Hollister Performance, Dismal Outlook & More

7 Analysts Have This to Say About Health Catalyst